Cipla-Novartis patent row: DIPP looking into merit of case
7th November 2014
Under Section 66 of IPA, Centre can revoke a patent in ‘public interest’ if it is of the opinion that a patent or the mode in which it is exercised is “mischievous to the State”
The Commerce and Industry Ministry is looking into the merit of Cipla’s demand for revocation of patents of Swiss drug major Novartis for respiratory drug Indacaterol citing the need for public health access.
Read more at source article www.business-standard.com